Ortaleza, Ervie, Jr. E.
HRN: 21-59-08 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/20/2022
CLINDAMYCIN 150MG/ML, 4ML (AMP)
07/20/2022
07/27/2022
IV
600mg
Q6h
Fracture
Waiting Final Action
Indication: Empiric Type of Infection: Bone & JointSkin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes